Research and development and general administrative expenses (GAAP) decreased year over year. This decrease resulted in a 15.6% reduction in net loss for Q2 2025 compared to Q2 2024. Strong clinical ...

Research and Development (R&D) expenses: R&D expenses were $22.3 million for the second quarter of 2025, compared to $27.8 million for the second quarter of 2024. General and Administrative (G&A) ...